SCHEMBL14975770

SCHEMBL14975770

CSc1ncc(C#N)c(Nc2csc3ncccc23)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.37
▸ GCK P35557 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ MAPT P10636 1/20 0.35
▸ SYK P43405 1/20 0.34
▸ AURKA O14965 1/20 0.34
▸ TRPV4 Q9HBA0 1/20 0.34
▸ LRRK2 Q5S007 2/20 0.33
▸ PTK2 Q05397 1/20 0.32
▸ PTK2B Q14289 1/20 0.32
▸ SLC2A1 P11166 1/20 0.32
▸ CLK1 P49759 1/20 0.31
▸ CLK2 P49760 1/20 0.31
▸ CLK3 P49761 1/20 0.31
▸ CDK5 Q00535 1/20 0.31
▸ DYRK1A Q13627 1/20 0.31
▸ CDK5R1 Q15078 1/20 0.31
▸ CLK4 Q9HAZ1 1/20 0.31
▸ DYRK1B Q9Y463 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14976747 0.74 SYK (0.46) SYKSLC2A1
SCHEMBL14976751 0.74 SYK (0.46) SYKSLC2A1
SCHEMBL5257876 0.72 KDM4E (0.54) KDM4EALDH1A1SYKAURKA
SCHEMBL21600835 0.71 KDM4E (0.40) KDM4EALDH1A1SMN1; SMN2MAPTSYK
SCHEMBL23487619 0.71 KDM4E (0.39) KDM4EALDH1A1SMN1; SMN2MAPTSYK
SCHEMBL21596403 0.70 INSR (0.40) KDM4EALDH1A1SMN1; SMN2MAPTPTK2
SCHEMBL30379728 0.70 INSR (0.40) KDM4EALDH1A1SMN1; SMN2MAPTPTK2
SCHEMBL23461740 0.69 SLC2A1 (0.57) ALDH1A1SMN1; SMN2MAPTSYKAURKA
SCHEMBL2480844 0.68 KDM4E (0.45) KDM4ESMN1; SMN2SYKAURKALRRK2
SCHEMBL23487589 0.68 PTK2 (0.50) ALDH1A1SMN1; SMN2MAPTLRRK2PTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140323418-A1 SELECTIVE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2014-10-30 — — US disclosed
US-20140323418-A1 SELECTIVE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2014-10-30 — — US disclosed
US-20140323418-A1 SELECTIVE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2014-10-30 — — US disclosed
EP-2782580-A1 SELECTIVE KINASE INHIBITORS Portola Pharmaceuticals, Inc. (US) 2014-10-01 — — EP disclosed
WO-2013078468-A1 SELECTIVE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-30 — — WO disclosed
WO-2013078468-A1 SELECTIVE KINASE INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2013-05-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323418-A1 SELECTIVE KINASE INHIBITORS SYK, BTK, LCK KDM4E 1113/4885GCK 668/4885ALDH1A1 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback